A rapidly expanding cutaneous tumour in the context of a Janus kinase inhibitor agent following allogenic stem cell transplant
No Thumbnail Available
Authors
Davies, Anna
Salisbury, Jon
Mehra, Varun
Papa, Sophie
Basu, Tanya
Check for full-text access
Issue Date
2022
Type
Article
Language
Keywords
Alternative Title
Abstract
Ruxolitinib is a selective, Janus kinase (JAK)1 and JAK2 inhibitor, which is effective in management of chronic graft-versus-host disease (cGvHD). However, the ensuing immunosuppressive effects can give rise to aggressive cutaneous tumours, including Merkel cell carcinoma. We present this case to highlight the development of cutaneous tumours with ruxolitinib, an increasingly used therapy, and the challenge of managing such tumours in the context of refractory cGvHD. Click here for the corresponding questions to this CME article.
Description
Citation
Publisher
License
Journal
Clinical and Experimental Dermatology
Volume
47
Issue
11